Articles about immunotherapy – Page 3 of 3

Juno stock plunges as additional deaths cause second hold on clinical trial for leukemia treatment

Juno Therapeutics, the Seattle-based biotech company developing immunotherapy treatments for cancer, announced it has placed a voluntary hold on the clinical… Read More

Chinese researchers become first to test CRISPR gene editing in humans, using immune cells to attack cancer

Researchers at Sichuan University in Chengdu, China, have injected the first CRISPR-edited cells into a patient. The procedure is part of… Read More

Fred Hutch unveils first-of-its-kind Immunotherapy Clinic, named after Bezos family

To many, immunotherapies — treatments that use a patient’s immune system to fight cancer— sound like something from an episode of… Read More

Study of Juno Therapeutics cancer treatment shows high rates of remission, possible promise for other drugs

A study published today on a Juno Therapeutics immunotherapy treatment for blood cancers shows that the drug and others like it could… Read More

Seattle startup raises $2M to expand technologies for immunotherapy

Take a quick browse through Seattle’s biotech scene, and you’ll notice a pattern. Immunotherapy — using the body’s immune system to fight… Read More

Juno posts loss as it amps up R&D spending for cancer trials

It’s been a busy quarter for Juno Therapeutics with several different immunotherapy trials underway and a big hiring push as it… Read More

Seattle just got another publicly traded biotech company

Seattle-based Aptevo Therapeutics completed a spinoff from Emergent BioSolutions Monday, making a debut in the public markets as a standalone company.… Read More

Juno Therapeutics resumes cancer clinical trial after removing suspect drug

Seattle-based Juno Therapeutics says it’s resuming a clinical trial of its immunotherapy treatment, a week after the Food and Drug… Read More

Alpine Immune Sciences raises $48 million for cancer and autoimmune treatment

Seattle’s Alpine Immune Sciences says it has closed a $48 million Series A financing round, to fund the development of… Read More

Fast-growing Adaptive Biotechnologies appoints president of new therapeutics division

Adaptive Biotechnologies, the heavily-funded Seattle bioinformatics company, today announced that Diego Miralles will become the president of a new division of… Read More